Intercept to Present at Upcoming Conference
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating in the following investor conference:
- Needham Healthcare Conference at 12:45 p.m. ET on Wednesday, March 28, 2018
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information aboutIntercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:Mark Vignola+1-646-747-1000[email protected]
Media inquiries: [email protected]
Investor inquiries: [email protected]
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
